Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain
…, S Wang, KM Kelly, J Haeussler, J Thipphawong - PAIN®, 2013 - Elsevier
Nerve growth factor (NGF) is increased in chronic pain conditions. This study examined
analgesic efficacy and safety of fulranumab, a fully human monoclonal anti-NGF antibody, in …
analgesic efficacy and safety of fulranumab, a fully human monoclonal anti-NGF antibody, in …
Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b/3 clinical trial
…, HR Brashear, G Novak, J Thipphawong… - JAMA …, 2021 - jamanetwork.com
Importance Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the
EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease. …
EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease. …
Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery
JB Thipphawong, N Babul, RJ Morishige… - The Journal of the …, 2003 - pubs.asahq.org
Background The AERx Pain Management System (Aradigm Corporation, Hayward, CA) is a
novel pulmonary delivery system for the systemic administration of morphine. The authors …
novel pulmonary delivery system for the systemic administration of morphine. The authors …
Pulmonary Insulin Administration Using the AERx® Insulin Diabetes System
J Thipphawong, B Otulana, P Clauson… - Diabetes Technology …, 2002 - liebertpub.com
… McElduff A, Clauson P, Mather LE, Okikawa J, Otulana B, Thipphawong J: The pharmacokinetic
and pharmacodynamics of a single and divided dose of inhaled insulin via the AERx …
and pharmacodynamics of a single and divided dose of inhaled insulin via the AERx …
Inhaled cytokines and cytokine antagonists
J Thipphawong - Advanced drug delivery reviews, 2006 - Elsevier
Cytokine and cytokine antagonist have provided novel and effective therapies for many
human diseases. A number of approved cytokines including the interferons (α, β and γ), …
human diseases. A number of approved cytokines including the interferons (α, β and γ), …
Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis …
M Hale, IC Tudor, S Khanna, J Thipphawong - Clinical therapeutics, 2007 - Elsevier
OBJECTIVE:: This study compared the efficacy and tolerability of a once-daily controlled-release
formulation of hydromorphone (OROS® hydromorphone, Janssen-Cilag, Beerse, …
formulation of hydromorphone (OROS® hydromorphone, Janssen-Cilag, Beerse, …
A randomized, double-blind comparison of OROS®hydromorphone and controlled-release morphine for the control of chronic cancer pain
M Hanna, J Thipphawong… - BMC palliative …, 2008 - Springer
Background Long-acting opioid formulations are advocated for maintaining pain control in
chronic cancer pain. OROS ® hydromorphone is a sustained-release formulation of …
chronic cancer pain. OROS ® hydromorphone is a sustained-release formulation of …
Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS)
…, J Cruz, J Jameson, M Klein, D Burt, J Thipphawong - Virology, 1999 - Elsevier
There is a need to improve the ability of subunit vaccines to induce CD8 + CTL responses in
humans, especially for vaccines used to prevent illness by organisms that undergo …
humans, especially for vaccines used to prevent illness by organisms that undergo …
Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo‐and active …
…, S Wang, KM Kelly, J Thipphawong - International journal of …, 2016 - Wiley Online Library
Aims The efficacy and safety of monotherapy with fulranumab, a monoclonal antibody that
neutralises human nerve growth factor (NGF), was evaluated compared with placebo and an …
neutralises human nerve growth factor (NGF), was evaluated compared with placebo and an …
Fulranumab for treatment of diabetic peripheral neuropathic pain: a randomized controlled trial
…, LJ Russell, M Fedgchin, KM Kelly, J Thipphawong - Neurology, 2014 - AAN Enterprises
Objective: To assess efficacy and safety of fulranumab, a fully human monoclonal antibody
against nerve growth factor, in patients with diabetic peripheral neuropathic pain (DPNP). …
against nerve growth factor, in patients with diabetic peripheral neuropathic pain (DPNP). …
